The short version of reversed-phase HPLC fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-10-25. Anything still debated is marked as such rather than presented as settled.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
| Property | Value | Notes |
|---|---|---|
| Origin | Fragment of a protein found in human gastric juice | Sequence corresponds to a fifteen-residue portion of the parent protein |
| Sequence | GEPPPGKPADDAGLV | Single linear chain, fifteen amino acids |
| Reported molecular weight | About 1419 daltons | Value quoted consistently in supplier and review literature |
| Regulatory status | Not an approved human medicine in the US or EU | Handled and sold as a research chemical |
| Sports status | Listed as prohibited | Falls under non-approved-substance categories in anti-doping codes |
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
Identity and purity are established using reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and yields a percentage purity. Mass spectrometry, typically with electrospray ionization, confirms the molecular mass against the expected value. Amino acid analysis or peptide mapping provides additional sequence confirmation. These methods are complementary, since chromatography measures how much material is present while mass spectrometry verifies what that material is. A certificate of analysis normally reports both.
Analytical results depend on the column, gradient, and detector wavelength chosen by the laboratory, so purity values from different sources are not always directly comparable. Water content, counterion form, and residual trifluoroacetate affect both mass and purity calculations. Microbiological and endotoxin testing are separate from chemical purity and are not covered by a standard chromatographic run. Buyers evaluating a material typically request the full method description rather than a single purity figure.
Lyophilized peptide powder is generally stored at minus twenty degrees Celsius or lower and kept away from light and moisture. Under these conditions degradation is slow, and sealed vials remain stable for extended periods. Once dissolved, the material is less stable, particularly in aqueous buffers near neutral pH, where hydrolysis and oxidation proceed faster. Solutions are usually kept cold and used within days to weeks. Repeated freeze-thaw cycles are avoided because they encourage aggregation.
==== Neurotrophic activity ==== Honokiol has been shown to promote neurite outgrowth and have neuroprotective effects in rat cortical neurons. Additionally, honokiol increases free cytoplasmic reforforason Ca2+ in rat cortical neurons. Honokiol is a weak CB2 receptor ligand but the naturally occurring derivative 4-O-methylhonokiol was shown to be a potent and selective cannabinoid CB2 receptor inverse agonist and to possess antiosteoclastic effects.
== Reception == Even prior to its publication people drew comparisons to The Hunger Games, Harry Potter or the Twilight series. Half Bad has also been compared to Nineteen Eighty-Four by George Orwell. It had already broken two Guinness World Records as the most translated book – and the most translated children's book – by a debut author before publication. A Publishers Weekly starred review states, "This grim and thrilling tale, first in a planned trilogy, features understated prose that lets readers' imaginations fill in the blanks, as well as a well-developed sense of Witch culture. Nathan, the damaged survivor of horrific abuse, is an unforgettable protagonist, and Green expertly captures his torment at being caught between the mutually hostile sides of his heritage." Kirkus Reviews states, "Green propels Nathan forward with the help of often underdeveloped secondary characters, who are overshadowed by the imaginary relationship Nathan builds with his father; it is this that keeps both Nathan and readers going." In a review for Tor.com, Kat Kennedy writes, "Sally Green's Half Bad is the perfect novel for inspiring one to despise all of humanity or fall onto the ground and weep pathetically. Needless to say, it is an excellent book." In a review for The Guardian, Philip Womack writes, "While there is nothing new here, Half Bad's combination of themes will no doubt be entirely attractive to a large section of readers.
A Loner addresses the themes of depression and the need for isolation, as Chanut was affected by these issues during the lockdown period, which coincided with the writing of the album. "A Thousand Miles Away", the last song on the album, marked the onset of Chanut's depression; the lyrics he wrote were about his father's death. David stated that A Loner's musical approach and themes addressed are "purely personal" and that the lyrics "evoke despair without making it an end in itself." "Dark, brooding and unapologetically downbeat on record", wrote Kerrang!'s Sam Law. In 2025, Toufouti stated that he found it interesting to elaborate on a sad individual or subject, as he felt there was material to develop. Saddiction continued in the vein of A Loner by being "more personal, more introspective", said Chanut. Before entering the studio, Toufouti slightly reworked the lyrics of "Neglect" to evoke his relationship with his father, who had just passed away. Lemaire wrote that the song's title, "Kowloon Lights", as well as the large block of buildings on the front cover of Sadditcion, point to a city theme. Chanut responded by elaborating on the feeling of loneliness in crowds, particularly in large cities like Paris, as well as on the mobile phone culture where everyone is focused on their own things. "Kowloon Lights" refers to the former densely populated enclave within the Hong Kong colony. Chanut commented on the grey buildings that made up the city and its colourful neon lights, often depicted in many Hong Kong films of the 1980s.
Sources: en.wikipedia.org
==== Elimination ==== Modafinil is eliminated 90% via metabolism and 10% via renal excretion. Modafinil, given as a single dose in radiolabeled form, is excreted 80% in urine and 1% in feces by 11 days post-administration. Urinary recovery as the major metabolite modafinil acid has been found to be 35 to 51% of a dose. Less than 10% of modafinil is excreted unchanged in urine. The elimination half-life of modafinil is in the range of 12 to 15 hours There is individual variation in this parameter depending on sex, cytochrome P450 genotypes, liver function, and renal function. The individual enantiomers of modafinil, armodafinil and esmodafinil, have substantially different pharmacokinetics due to differing elimination profiles. Both armodafinil and esmodafinil are eliminated in a monophasic manner. However, armodafinil has a half-life of 10 to 17 hours, while esmodafinil has a half-life of 3 to 5 hours (3–4 times shorter). Consequently, modafinil has a biphasic elimination profile, with esmodafinil being eliminated much more rapidly than armodafinil. Armodafinil and modafinil have shown virtually identical elimination half-lives of approximately 12 to 16 hours in directly comparative studies. However, due to the biphasic elimination profile of modafinil, armodafinil shows higher levels than modafinil from 4 to 6 hours after administration and about 40% higher area-under-the-curve (AUC) levels than modafinil. Moreover, armodafinil showed 42% lower peak-to-trough variation than modafinil with once-daily administration at steady state.
Soy sauce allergy not caused by soy or wheat allergy is rare. Most varieties of soy sauce contain wheat, to which some people have a medical intolerance. However, protein hydrolysis (fermentation or industrial) breaks down gluten, so some soy sauces may end up tolerable to gluten-intolerant individuals with no detectable gluten left. Japanese tamari soy sauce is traditionally wheat-free, and some tamari available commercially today is wheat- and gluten-free. Acid-hydrolyzed vegetable protein is non-allergenic due to the completeness of protein breakdown.
=== Bingham plastic === Fluids that have a linear shear stress/shear strain relationship but require a finite yield stress before they begin to flow (the plot of shear stress against shear strain does not pass through the origin) are called Bingham plastics. Several examples are clay suspensions, drilling mud, toothpaste, mayonnaise, chocolate, and mustard. The surface of a Bingham plastic can hold peaks when it is still. By contrast Newtonian fluids have flat featureless surfaces when still.
Sources: en.wikipedia.org
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.
The peptide was named after a protein fraction found in human gastric juice, and the shorter form was called body protection compound. That phrase was shortened to the abbreviation BPC. The number 157 refers to a laboratory designation used in the original isolation work.
Its sequence corresponds to a segment of a protein present in gastric secretions, but the material supplied for research is made synthetically. No commercial product is purified from human or animal tissue. The synthetic route is used because it gives a defined chain length and a reproducible sequence.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.